The Administration Core is the central core of the Mayo Clinic SPORE in Ovarian Cancer. It will provide organizational support for the leadership of the SPORE, facilitate communication among the component activities of the SPORE, and provide an organizational portal for collaborations outside the SPORE. Specifically, the Administration Core will: 1) provide leadership, organizational support, and financial management for SPORE investigators;2) oversee formal procedures for systematic scientific review of SPORE research projects;3) oversee and coordinate the efforts of all cores to ensure that the research projects are supported effectively;4) monitor'accrual, including minority accrual, to all SPORE clinical trials and biospecimen collections;5) provide administrative support to the Developmental Research Program and Career Developmental Program;6) assure ongoing integration and participation of the Ovarian SPORE in the activities of the Mayo Clinic Cancer Center;7) facilitate activities of the Ovarian SPORE advocates; 8) serve as the administrative liaison between the Mayo Clinic SPORE and the NCI SPORE Program, other Mayo SPOREs, and external collaborators;and 9) communicate SPORE-related research developments among the Mayo Clinic SPORE investigators, to the scientific community at large, and to the public. Dr. Hartmann will direct the Administration Core, in close consultation with the SPORE Co-PI/Administration Core Co-Director, and Executive Committee, to maximize the effectiveness of the Ovarian SPORE effort and its clinical-translational impact.
The Administration Core provides the organizational infrastructure necessary to perform the work proposed in this SPORE application.
|Wu, Chenming; Luo, Kuntian; Zhao, Fei et al. (2018) USP20 positively regulates tumorigenesis and chemoresistance through ?-catenin stabilization. Cell Death Differ 25:1855-1869|
|Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187|
|Li, Lei; Liu, Tongzheng; Li, Yunhui et al. (2018) The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization. Oncogene 37:2422-2431|
|Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430|
|Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348|
|Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987|
|Wahner Hendrickson, Andrea E; Menefee, Michael E; Hartmann, Lynn C et al. (2018) A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. Clin Cancer Res 24:744-752|
|Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169|
|Knijnenburg, Theo A; Wang, Linghua; Zimmermann, Michael T et al. (2018) Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep 23:239-254.e6|
|Jung, DeokBeom; Khurana, Ashwani; Roy, Debarshi et al. (2018) Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer. Sci Rep 8:2487|
Showing the most recent 10 out of 294 publications